Indian Super League (ISL) football team Bengaluru FC were asked to leave the Maldives on Sunday by the country's sports minister, after some players breached COVID-19 protocols ahead of their AFC Cup playoff tie with Eagles FC.
Maldives Minister of Youth, Sports and Community Empowerment Ahmed Mahloof took to Twitter to call for the Indian team to leave the country for breaching guidelines set by the Health Protection Agency (HPA) before their match on May 11.
"Unacceptable behaviour from @bengalurufc breaching the strict guidelines from HPA," Mahloof said. "The club should leave... immediately as we can't entertain this act.
"We have informed FAM (Football Association of Maldives) that we cannot hold the match, and asked them to make arrangements for @bengalurufc's departure. We will be in further correspondence with AFC... to postpone the group stage."
The AFC later confirmed that all AFC Cup south zone group stage matches in the Maldives had been postponed.
Group D matches were originally scheduled to be held in the capital Male from May 14-21. The AFC did not give revised dates for the games.
"Participating clubs who have travelled to Maldives will be required to arrange for their return home while adhering to the COVID-19 health and travel protocols put in place by the country," the AFC said in a statement.
"At the same time, the AFC is in contact with all other participating clubs and officials who have not entered the Maldives to cancel their travel arrangements."
Group D includes India's ATK Mohun Bagan, Bashundhara Kings of Bangladesh, Maldives' Maziya Sports & Recreation and the winner of the playoff.
Bengaluru FC CEO Parth Jindal said on Twitter that the club would sanction three members of the travelling party.
"On behalf of @bengalurufc, I am extremely sorry for the inexcusable behavior of three of our foreign players/staff while in Male - the strictest action will be taken against these players/staff," Jindal said.
Earlier, Group J matches in Hong Kong were postponed from May to June due to challenges caused by the COVID-19 pandemic.
The 2020 edition of the AFC Cup was cancelled due to the COVID-19 pandemic when quarantine regulations in many nations made international travel almost impossible.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.